Metabolomic Analysis of Systemic Sclerosis

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Nov 19, 2014

Keywords

ClinConnect Summary

This clinical trial is studying a condition called systemic sclerosis (SSc), which is often linked to a disease where blood vessels are affected, like Raynaud's disease. The researchers aim to find specific metabolic markers—substances in the body that can help with diagnosis and prognosis—so that SSc can be diagnosed earlier, especially during the early stages of the disease. The study will compare the metabolic profiles of patients who have recently been diagnosed with SSc (less than 3 years) to those who have had the disease for longer (more than 3 years), as well as to individuals with related conditions and healthy people.

To participate in this trial, you need to meet certain criteria. Patients with SSc, undifferentiated connective tissue disease (a related condition), isolated Raynaud's disease, or specific vascular diseases may be eligible. Healthy individuals who do not have any of these conditions are also welcome as control subjects. Participants will provide blood, urine, and skin samples, and they can expect to contribute to important research that may lead to better understanding and treatment of SSc. This study is currently recruiting participants of all genders aged 65 to 74, and it’s a great opportunity to help advance medical knowledge in this area.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Group 1 (scleroderma) : Patients with ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001)
• • Group 2 (UCDT) : Patients with criteria proposed by Mosca et al. (1998)
• • Group 3 (Raynaud) : Patients with primary and isolated Raynaud disease
• • Group 4 (vascular disease) : Patients with type 2 diabetes, occlusive vascular disease, history of myocardial infarction or ischemic stroke
• • Group 5 (healthy control) : healthy subjects (no sign of connective tissue disease, no Raynaud, no vascular disease)
• Exclusion criteria:
• • Group 1 (scleroderma) : Patients not fulfilling ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001), or with another auto-immune disease
• • Group 2 (UCDT) : Patients not fulfilling criteria proposed by Mosca et al. (1998)
• • Group 3 (Raynaud) : Patients with no Raynaud disease
• • Group 4 (vascular disease) : Patients with no vascular disease
• • Group 5 (healthy control) : Patients with sign of connective tissue disease, Raynaud, or vascular disease)